Panacea Life Sciences Holdings, Inc. Completes Beta Testing and Prepares for National Launch of Telemedicine and Peptide
BeniVita completes beta of proprietary technology; distribution and marketing relationships expected to be extended to ...
Model output · Signal date 2026-10-16
Panacea Life Sciences Holdings, Inc. (PLSH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · OTC
Rating · 90D
▲ Bullish
Exact rating locked
90-day forecast
Sign up free to reveal
30-day forecast
Total
Rank in coverage
Top 35%
of 5172 stocks scored
Rank correlation · 90D
-9.0%
Spearman, 357 dates
Market Cap
$6M
small-cap · #23 of 28 peers
Summary
Panacea Life Sciences Holdings, Inc. (PLSH) stock forecast summary
Our AI ranks Panacea Life Sciences Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Panacea Life Sciences Holdings, Inc. is a small-cap company with a market capitalization of $6M. It ranks number 23 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For PLSH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PLSH included.
Follow PLSH freePrice
PLSH price chart and AI forecast
Cross-section · 2026-10-16
How PLSH ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2024-03-31
Panacea Life Sciences Holdings, Inc. (PLSH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | PLSH | Rank |
|---|---|---|
| Market Cap | $6M | 23/28 |
Profitability & Margins
| Metric | PLSH | Rank |
|---|---|---|
| ROA | -41.3% | 20/24 |
| Gross Margin | 44.2% | 10/23 |
| Operating Margin | -172.2% | 21/24 |
| Net Margin | -256.1% | 21/22 |
| EBT Margin | -258.2% | 23/25 |
Financial Health
| Metric | PLSH | Rank |
|---|---|---|
| Interest Coverage | -2.5x | 13/22 |
Cash Flow
| Metric | PLSH | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | 20/29 |
Income Statement
| Metric | PLSH | Rank |
|---|---|---|
| Operating Income | -$5M | 17/27 |
| Net Income | -$7M | 13/24 |
| Cost of Goods Sold | $1M | 19/24 |
Dividend & Shareholder Information
| Metric | PLSH | Rank |
|---|---|---|
| Shares Outstanding | 68M | – |
Balance Sheet Highlights (USD millions)
| Total Liabilities | $27M |
Quarterly Financial Reports
PLSH quarterly financials and insider trading
Industry Peers · Medicinal Chemicals & Botanical Products
Panacea Life Sciences Holdings, Inc. (PLSH) industry peers
Companies classified under the same SEC industry code as Panacea Life Sciences Holdings, Inc. (Medicinal Chemicals & Botanical Products): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▶ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▶ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▶ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| FTLF Fitlife Brands, Inc. | ▶ | $81M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| BTMD Biote Corp. | ▲ | $35M |
| CHUC Charlie's Holdings, Inc. | ▶ | $27M |
| MRMD Marimed Inc. | ▲ | $23M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| BON Bon Natural Life Ltd | ▼ | $7M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $310K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▲ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
Where PLSH sits on the market map
Life Sciences · Medicinal Chemicals & Botanical Products
News
Panacea Life Sciences Holdings, Inc. (PLSH) stock news
Panacea Life Sciences Holdings (OTCID: PLSH) and Benivita Inc. Launch Benivita PLSH -- a New Era in Direct-to-Consumer Virtual Benefits
Benivita PLSH will combine three powerhouse elements: PLSH's operational and financial infrastructure, Benivita's global expertise in direct and multi-level marketing, and New Benefits, Inc.'s decades ...
Panacea Life Sciences Hldgs Inc (PLSH)
We are actively working to enhance your experience by translating more content. However, please be aware that the page you are about to visit has not yet been translated. We appreciate your ...
FAQ
Panacea Life Sciences Holdings, Inc. (PLSH) stock forecast FAQ
What is the Panacea Life Sciences Holdings, Inc. (PLSH) stock forecast?
Our AI ranks Panacea Life Sciences Holdings, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Panacea Life Sciences Holdings, Inc. stock predictions?
For PLSH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Panacea Life Sciences Holdings, Inc. forecasts updated?
Panacea Life Sciences Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Panacea Life Sciences Holdings, Inc.'s industry peers?
32 issuers in our coverage, PLSH included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.